Patients were matched 1:1 using propensity scores to balance demographics, comorbidities, prior inflammatory bowel disease treatments, healthcare use, and baseline steroid exposure
Richie, J.P., Nichenametla, S., Neidig, W., Calcagnotto, A., Haley, J.S., Schell, T.D., and Muscat, J.E
In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it
By week 3 or 4 of the pattern, nausea and GI symptoms worsen, and patients don't connect it to the timing change